NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

KPL-716-新洞察與市場預測:2030年

KPL-716- Emerging Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 974742
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
KPL-716-新洞察與市場預測:2030年 KPL-716- Emerging Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

KPL-716是一種靶向OSMRB的研究性全人類單克隆抗體,可介導IL-31和OSM的信號傳導,這是涉及瘙癢,炎症和纖維化的兩種關鍵細胞因子。Kiniksa認為KPL-716是開發中唯一同時靶向兩種途徑的單克隆抗體。

未來幾年,由於全球對治療適應症的廣泛研究和不斷增加的醫療保健支出,KPL-716的市場前景將發生變化。這將擴大市場規模,使藥品製造商能夠更擴大滲透到市場中。

這些公司和學者正在努力評估挑戰並尋找可能影響KPL-716優勢的機會。正在開發的療法集中於治療/改善疾病狀況的新方法。

其他批准用於該疾病的產品正在給KPL-716帶來市場競爭,並且在不久的將來推出後期新興療法將極大地影響市場。

監管法規里程碑,開發活動以及一些關鍵發現的詳細說明提供了KPL-716當前的市場情況。

我們將通過對KPL-716從2017年到2030年銷售數據的深入分析來確定市場上KPL-716的整體情況,為客戶提供有關其治療產品組合的決策過程的支持。

本報告全面涵蓋7個主要市場上慢性自發性蕁麻疹臨床實驗藥。提供有關2020-2030年調查期間美國,歐洲5個國家(德國,法國,意大利,西班牙,英國)和日本7個主要市場的KPL-716詳細概要。產品詳細內容中包含作用機制,劑量管理,合成途徑,法規的里程碑的研究開發活動,以及其他開發活動。再加上市場預測、 SWOT分析,市場上競爭趨勢,及其他新治療方法等未來市場趨勢。

目錄

第1章 藥物概要

  • 產品詳細內容
  • 作用機制
  • 劑量與管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭趨勢

第6章 其他的新治療方法

第7章 附錄

第8章 報告購買選擇

目錄
Product Code: DIDM0123

"KPL-716- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the KPL-716 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

KPL-716 is an investigational fully-human monoclonal antibody that targets OSMRB, which mediates signaling of IL-31 and OSM, two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes KPL-716 to be the only monoclonal antibody in development that targets both pathways simultaneously.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around KPL-716.
  • The report contains forecasted sales for KPL-716 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Chronic Spontaneous Urticaria.
  • The report also features the SWOT analysis with analyst insights and key findings of KPL-716.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KPL-716 Analytical Perspective by DelveInsight

  • In-depth KPL-716 Market Assessment

This report provides a detailed market assessment of KPL-716 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • KPL-716 Clinical Assessment

The report provides the clinical trials information of KPL-716 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence KPL-716 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic Spontaneous Urticaria are giving market competition to KPL-716 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of KPL-716.
  • Our in-depth analysis of the forecasted sales data of KPL-716 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KPL-716.

Key Questions:

  • Which company is developing KPL-716 along with the phase of the clinical study?
  • What is the technology utilized in the development of KPL-716?
  • What is the product type, route of administration and mechanism of action of KPL-716?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KPL-716 development?
  • What are the key designations that have been granted to KPL-716?
  • What is the forecasted market scenario of KPL-716?
  • What is the history of KPL-716 and what is its future?
  • What is the forecasted sales of KPL-716 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to KPL-716?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 KPL-716, Description
  • Table 2 KPL-716, Clinical Trial Description
  • Table 3 KPL-716, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of KPL-716
  • Figure 2 Patent Details, KPL-716
  • Figure 3 KPL-716, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 KPL-716, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 KPL-716, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 KPL-716, Japan Market Size from 2020 to 2030 (in Millions USD)